Luveris®(Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (LH <1.2 IU/L)
This study has been terminated.
(Please see "Purpose" statement)
Information provided by (Responsible Party):
First received: May 20, 2006
Last updated: June 12, 2012
Last verified: June 2012
Sponsor has decided to discontinue Luveris® in the US due to level of customer demand for this product, and not due to any efficacy or safety concerns.
Drug: lutropin alfa
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
||A Phase IV , Multicenter, Randomized, Double-blinded, Clinical Trial to Confirm the Efficacy of the 75 IU Dose of Luveris® vs. Placebo When Administered With Follitropin Alfa for Induction of Follicular Development and Pregnancy in Hypogonadotropic Hypogonadal Women With Profound LH Deficiency, as Defined by a Baseline LH Level <1.2 IU/L.
Primary Outcome Measures:
- Time to clinical pregnancy. Clinical pregnancy will be determined as the presence of a fetal sac and heartbeat on pelvic ultrasound 35-42 days post-hCG. [ Time Frame: 35-42 days post-hCG ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Follicular Development, Ovulation and Cumulative Pregnancy Rate [ Time Frame: Various time points ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||April 2012 (Final data collection date for primary outcome measure)
Placebo Comparator: 1
Gonal-f® + a placebo
Subcutaneous injection once daily until criteria for ovulation triggering is met (21 day max)
Gonal-f® + lutropin alfa 25 IU
Drug: lutropin alfa
Once daily Subcutaneous injection until criteria for ovulation triggering is met (21 day max)
Gonal-f® + lutropin alfa 75 IU
Drug: lutropin alfa
Once daily subcutaneous injection until criteria for ovulation triggering is met (21 day max)
To confirm the efficacy of the 75 IU dose of Luveris® compared to placebo when administered concomitantly with follitropin alfa for induction of clinical pregnancy in women with hypogonadotropic hypogonadism and profound LH deficiency (LH <1.2 IU/L), and to study the efficacy of a lower dose (25 IU) of Luveris® compared to placebo when administered concomitantly with follitropin alfa for induction of follicular development in women with hypogonadotropic hypogonadism and profound LH deficiency (LH <1.2 IU/L).
|Ages Eligible for Study:
||18 Years to 40 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Be premenopausal, between 18 and 40 years of age inclusive on the day of consent.
- Have a clinical history of hypogonadotropic hypogonadism.
- Have no prior treatment cycles with gonadotropins or GnRH (gonadotropin naïve).
- Have discontinued estrogen progesterone replacement therapy at least one month before the screening procedure.
- Have primary or secondary amenorrhea.
- Have a negative progestin challenge test performed during screening.
- Have the following hormonal values in a centrally analyzed fasting blood sample, drawn within 6 weeks before initiation of treatment:
FSH: <5 IU/L LH: <1.2 IU/L
- Have an endovaginal pelvic ultrasound scan showing (i) no clinically significant uterine abnormality, (ii) no ovarian tumor or cyst, and (iii) £13 small follicles (mean diameter £10 mm) on the largest section through each ovary.
- Have a normal cervical pap smear within 6 months of the initial visit.
- Where indicated, have a normal or unchanged computed tomography (CT) scan or nuclear magnetic resonance (NMR) scan of the hypothalamic pituitary region on file.
- Have a body mass index (BMI) between 18.4 and 31.4 kg/m2
- Be willing and able to comply with the protocol for the duration of the study
- Have given written informed consent prior to any study related procedure.
- Any medical condition which in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug.
- Any pre existing medical condition which would compromise the subject's ability to conceive in vivo or to successfully complete a pregnancy. In case of doubt this should be discussed with Serono's Medical Director.
- Ongoing pregnancy
- Clinically important systemic disease (e.g. insulin-dependent diabetes mellitus, epilepsy, serious migraine, intermittent purpura, hepatic, renal or cardiovascular disease, serious corticoid-dependent asthma).
- Known infection with HIV, Hepatitis B or C.
- Ovarian enlargement or cyst of unknown etiology.
- Abnormal gynecological bleeding of undetermined origin.
- Previous or current hormone dependent tumor.
- Known active substance abuse or eating disorder.
- Known CNS Lesions: In cases where HH is secondary to a CNS lesion or its treatment, the subject will not be eligible without consulting Serono's Medical Director.
- Exercise program exceeding 10 hours per week.
- Is planning to undergo in vitro fertilization, intracytoplasmic sperm injection or another assisted reproductive technology (ART) procedure, other than intrauterine insemination, in the course of a study treatment cycle.
- Currently undergoing treatment with psychotropic medication or with any other medication known to interfere with normal reproductive function (e.g. neuroleptics, dopamine antagonists). Any questions about specific medications should be addressed to Serono's Medical Director
Please refer to this study by its ClinicalTrials.gov identifier: NCT00328926
|U.S. Medical Information, 1-888-275-7376
|Rockland, Massachusetts, United States, 02370 |
||Zourab Bebia, MD
||Merck Serono S.A., Geneva
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 20, 2006
||June 12, 2012
||United States: Food and Drug Administration
Keywords provided by EMD Serono:
Hypogonadotropic Hypogonadism (LH <1.2 IU/L)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on June 18, 2013
Endocrine System Diseases